Mirati Therapeutics gets a Breakthrough designation for its colorectal cancer drug


Shares of Mirati Therapeutics Inc. MRTX, -1.96% jumped 6.0% in premarket trading on Thursday after the company said the Food and Drug Administration granted a breakthrough therapy designation to Krazati as a treatment for colorectal cancer. The drug is already approved to treat certain kinds of non-small cell lung cancer. Mirati’s stock has tumbled 71.8% so far this year, while the broader S&P 500 SPX, +0.59% is down 18.6%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: These are the China stories to watch in 2023
Next articleNerdWallet: There’s still time to make these smart tax moves before the end of the year—your future self will thank you


Please enter your comment!
Please enter your name here